

Partnering opportunities

- Core therapeutic areas
- Technology platforms
- Out licensing and divestments
- Other areas

We are looking for high-value, truly differentiating first or best-in-class treatments in:

Cardiovascular, renal & metabolic (CRM)

- Heart Failure, hypertension and atrial fibrillation
- Atherosclerosis and multiple CV risk factor management
- Metabolic (including obesity)
- Autosomal dominant polycystic kidney disease (ADPKD)
- Glomerular diseases (Alport, FSGS)
- IgA nephropathy (IgAN)



Thierry Droz-Georget

Contact

Immunology

- Rheumatology
- Dermatology
- Disease modifying osteoarthritis
- Nucleic acid sensing & inflammasome
- Tolerance induction
- Allergy

□

Contact

Neuroscience

- MS and immuno-neurological diseases
- Neurodegenerative diseases
- Neuromuscular diseases



Chi-Chi Zhu

Contact

Oncology

- Breast cancers

- Prostate cancers
- Lung cancers
- Colorectal and pancreatic cancers
- Radioligand therapy (RLT): novel isotopes, chelators vectors and targets
- Non-Hodgkin lymphoma (NHL)
- Acute myeloid leukemia (AML)/ Myelodysplastic syndrome (MDS)
- Multiple myeloma (MM)
- Non-malignant hematology



Markus Werner

Contact

We are looking for innovative approaches to accelerate the development of therapeutics:

Chemistry

- Artificial intelligence/Machine learning (AI/ML)
- Synthesis and profiling automation
- Novel approaches to accelerate discovery and synthesis of new molecular entities
- Tissue targeting vectors for siRNA or Radioligand therapy (RLT)
- Preclinical small molecule leads for innovative therapies



Avi Spier

Contact

Biotherapeutics

- Novel approaches/platforms that leverage AI/ML and wet lab capabilities for challenging and multi-specific antibody discovery.

- Targeted delivery and selective tropism to key tissues/cell types
- Biodistribution, intracellular trafficking and stability assessment of Adeno-associated virus (AAV), Radioligand therapeutics (RLTs), and targeted siRNA conjugates



Gianfranco de Pascale

Contact

Cell and gene therapy

- Novel T-cell-based therapy approaches for haematology & solid tumors
- Approaches to reduce AAV immunogenicity
- NextGen gene editing (non-viral)
- Novel capsids with focus on CNS and Ophthalmology targeting



Markus Werner (Oncology)

Contact



Elizabeth Leshen (Rare diseases and neuroscience)

Contact

xRNA

- Targeted delivery approaches for RNA therapeutics to extra-hepatic tissues/cell types
- Innovative siRNA chemistry platforms
- In vivo/In vitro platforms to identify and validate siRNA targets



Gianfranco de Pascale

Contact

Radioligand therapy

- Discovery of new RLT binders (“vectors”)
- Differentiated RLT assets that complement current pipeline and disease focus with novel isotopes, chelators or vectors for tumor specific RLT delivery
- Explore various combination approaches which are synergistic with RLTs

□

Marcel Reichen

Contact

Out licensing and divestments

Novartis is open to discussing the divestment of certain commercial products in different regions, as well as granting licenses to development-stage compounds that have been de-prioritized due to strategic reasons.



Out licensing

Sven Werner

[Contact](#)



Divestments

Jean Marc Séquier

Contact

Artificial intelligence | Machine learning | Digital

We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to:

- Enable deeper understanding of disease
- Power small and large molecule design
- Increase predictive safety
- Improve trial design



Cynthia Hong

Contact

Precision medicine

Interested in biomarker and diagnostic technologies that are designed to optimize the efficiency, safety and therapeutic benefit of our drugs. Technologies may include genomic and proteomic testing as well as artificial intelligence driven solutions.



Guy Greiveldinger

Contact



Frank Dieterle

Contact

Global health

Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including emerging and tropical infectious diseases.



Charles Bailey

[Contact](#)

Discover more



Where to meet us

[See which events Novartis will be attending](#)



Leadership team

Get to know the Corporate & Business Development team



Our approach

Discover how we collaborate to address some of society's most challenging healthcare issues.

Source URL: <https://prod1.novartis.com/partnering/partnering-opportunities>

List of links present in page

1. <https://prod1.novartis.com/partnering/partnering-opportunities>
2. [#tabcore-therapeutic-areas-205371](#)
3. [#tabtechnology-platforms-205376](#)
4. [#tababout-licensing-and-divestments-398296](#)
5. [#tabother-areas-205381](#)
6. <https://prod1.novartis.com/node/600066>
7. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
8. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
9. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
10. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
11. <https://prod1.novartis.com/node/600066/printable/print>
12. <https://prod1.novartis.com/node/600066/printable/pdf>
13. <https://prod1.novartis.com/node/600101>
14. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
15. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
16. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
17. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
18. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>

19. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
20. <https://prod1.novartis.com/node/600101/printable/print>
21. <https://prod1.novartis.com/node/600101/printable/pdf>
22. <https://prod1.novartis.com/node/665681>
23. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
24. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
25. <https://prod1.novartis.com/node/665681/printable/print>
26. <https://prod1.novartis.com/node/665681/printable/pdf>
27. <https://prod1.novartis.com/node/600106>
28. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
29. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
30. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
31. <https://novartis.partneringplace.com/SubmissionUI/novartis/submission>
32. <https://prod1.novartis.com/node/600106/printable/print>
33. <https://prod1.novartis.com/node/600106/printable/pdf>
34. <https://prod1.novartis.com/partnering/partnering-event-calendar>
35. <https://prod1.novartis.com/partnering/partnering-leadership-team>
36. <https://prod1.novartis.com/partnering/our-approach-partnering>